Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
Nab-paclitaxel
100%
Concurrent Cisplatin
100%
5-fluorouracil (5-FU)
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Concurrent Radiation
100%
Cisplatin
100%
Radiation Therapy
41%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
41%
Cisplatin Therapy
41%
Progression-free Survival
25%
Disease-specific Survival
25%
Overall Survival
16%
Phase II Trial
16%
Relapse Rate
16%
Cetuximab
16%
Tumor
8%
Performance Status
8%
Comorbidity
8%
High Dose
8%
Sufficient Follow-up
8%
Treatment-related Mortality
8%
Overall Survival Rate
8%
Organ Function
8%
Efficacy Endpoint
8%
Cause of Death
8%
Smokers
8%
Bolus
8%
Oropharynx
8%
T1 Tumor
8%
Locally Advanced
8%
Virus Status
8%
Hypopharynx
8%
Function Status
8%
Medicine and Dentistry
Paclitaxel
100%
Cisplatin
100%
Fluorouracil
100%
Wart Virus
100%
Head and Neck Squamous Cell Carcinoma
100%
Radiation Therapy
41%
Progression Free Survival
25%
Overall Survival
25%
Disease Specific Survival
25%
Neoplasm
16%
Recurrence Risk
16%
Cetuximab
16%
Phase II Trials
16%
Survival Rate
8%
Smoking
8%
Drug Megadose
8%
Oropharynx
8%
Larynx
8%
Hypopharynx
8%
Comorbidity
8%
Immunology and Microbiology
Wart Virus
100%
Squamous Cell
100%
Neck
100%
Overall Survival
25%
Progression Free Survival
25%
Disease Specific Survival
25%
Cetuximab
16%
Drug Megadose
8%
Oropharynx
8%
Hypopharynx
8%
Comorbidity
8%